LABORATORY STUDIES
Oral administration of lactic acid bacteria has been shown to effectively reduce DNA damage, induced by chemical carcinogens, in gastric and colonic mucosa in rats. Pool-Zobel et al. (46) reported, using the comet assay, that Lactobacillus acidophilus, L. gasseri, L. confusus, Streptococcus thermophilus, Bifidobacterium breve and B. longum were antigenotoxic toward N-nitro-N-nitrosoguanidine (MNNG). These bacteria were also protective toward 1,2-dimethylhydrazine (DMH)-induced genotoxicity. Metabolically active L. acidophilus cells, as well as an acetone extract of the culture, prevented MNNG-induced DNA damage, while heattreated L. acidophilus was not antigenotoxic. Among different cell fractions from L. acidophilus, the peptidoglycan fraction and whole freeze-dried cells were antigenotoxic.
Certain strains of lactic acid bacteria have also been found to prevent putative preneoplastic lesions or tumours induced by carcinogens. Goldin et al. (17) showed that a specific strain of L. casei subsp. rhamnosus designated GG can interfere with the initiation or early promotional stages of DMH-induced intestinal tumorigenesis and that this effect is most pronounced for animals fed a high-fat diet. Overnight cultures of L. acidophilus also inhibited the formation of aberrant crypt foci (ACF), which are thought to be precursor and tumour multiplicity and also reduced tumour volume induced by AOM in rats (61) . Ingestion of B. longum also significantly inhibited AOM-induced cell proliferation, ornithine decarboxylase activity and expression of the ras-p21 oncoprotein. There is additional direct evidence for anti-tumour activities of lactic acid bacteria obtained in studies using pre-implanted tumour cells in animal models. It has been demonstrated that feeding of fermented milk or cultures containing lactic acid bacteria inhibited the growth of tumour cells injected into mice (12, 31). Repeated intralesional injection of live or dead Bifidobacterium cells inhibited the growth of Meth-A tumour cells transplanted s.c. into syngenic BALB/c mice (30). Sekine et al. (63) using whole peptidoglycan isolated from B. infantis strain ATCC15697, reported that a single subcutaneous injection significantly suppressed tumour growth. In addition, five intralesional injections resulted in 70% tumour regression in the mice.
More recently, mindful of the fact that the composition and metabolic activities of the intestinal flora of experimental animals are significantly different from those of humans (24), we exploited human flora associated (HFA) mice to test the effects of a probiotic mixture on a parameter of relevance for colon carcinogenesis i.e. DNA adduct formation. Indeed, the results from a previous report, from our laboratory, demonstrated that human intestinal microflora had different effects than mouse microflora concerning DNA adduct formation after exposure to mutagens (20). The probiotic mixture, Biothree®, used in this study contained Streptococcus faecalis T-110, Clostridium butyricum TO-A and Bacillus mesentericus TO-A, which are acid resistant in contrast to most bacteria, which do not survive contact with gastric acid. It has been reported that S. faecalis T-110 and C. butyricum TO-A showed strong symbiosis with each other and the growth of enteropathogens (enterotoxigenic Escherichia coli, Salmonella typhimurium, Vibrio parahaemolyticus, C. difficile and C. botulinum) was inhibited in mixed cultures of S. faecalis T-110 and C. butyricum TO-A (62). It has also been reported that B. mesentericus TO-A stimulated the growth of Bifidobacterium by producing 3,3-dihydroxyazetidine (26, 56). Biothree® is used as a clinical therapy in Japan. It is effective for the improvement of symptoms caused by abnormal intestinal flora, i.e. diarrhoea and constipation. Interestingly, the results of this study demonstrated that the above probiotic mixture had an effect to significantly decrease the DNA adduct formation in the colonic epithelium induced by the food mutagen 2-amino-9H-pyrido [ intake of dairy products is associated with a decreased risk of colon cancer (28). In a cohort study in the Netherlands, it was shown that the intake of fermented dairy products was not significantly associated with colorectal cancer risk in an elderly population with a relatively wide variation in dairy product consumption, although a weak nonsignificant inverse association with colon cancer was observed (29).
MECHANISMS BY WHICH LACTIC ACID BACTERIA INHIBIT COLON CANCER
The precise mechanisms by which lactic acid bacteria may inhibit colon cancer are presently unknown. However, such mechanisms might include: enhancing the host's immune response; binding and degrading potential carcinogens; quantitative and/or qualitative alterations in the intestinal microflora incriminated in producing putative carcinogen(s) and promoters (e.g. bile acid-degrading bacteria); producing antitumorigenic or antimutagenic compounds in the colon; alteration of the metabolic activities of intestinal microflora; alteration of physicochemical conditions in the colon; effects on physiology of the host (Fig. 1) .
Enhancing the Host's Immune Response
One explanation for tumour suppression by lactic acid bacteria may be mediated through an immune response of the host. Sekine et al. (63) suggested that B. infantis stimulates the host-mediated response, leading to tumour suppression or regression. In addition, there are studies to suggest that lactic acid bacteria play an important role and function in the host's immunoprotective system by increasing specific and non-specific mechanisms to have an anti-tumour effect (11, 33, 60 in the colon (66) . One hypothesis regarding colon carcinogenesis involves a cytotoxic effect on the colonic epithelium exerted by bile acids in the aqueous phase of faeces (soluble bile acids), followed by an increased proliferation of cells in the intestine (4). It has been demonstrated that a 6-week administration of L. acidophilus to colon cancer patients resulted in lower concentrations of soluble bile acids in faeces (34). Although the decrease in the concentration of bile acids in this fraction of faeces was not significant (perhaps due to a low number of patients or a limited supplementation period), it was of interest that a definite trend towards decreased levels of soluble bile acids was observed in the colon cancer patients receiving L. acidophilus fermented milk supplements. In another study, patients with colonic adenomas participated in a 3-month study, where L. acidophilus was administered together with B. bifidum (7). During this period, the faecal pH was reduced significantly and patients having a higher proliferative activity in the upper colonic crypts than that calculated for subjects at low risk for colon cancer, showed a significant decrease after therapy with the lactic acid bacteria. In view of the results in the above mentioned study (34) it is interesting to speculate that this latter effect was in part due to decreased levels of bile acids in the aqueous phase of faeces.
Effects on Physiology of the Host Lactobacilli are one of the dominant species in the small intestine, and these micro-organisms presumably affect metabolic reactions occurring in this part of the gastrointestinal tract. The ileal mucosa (64) as well as the colonic mucosa (13) has the capacity to absorb mutagenic compounds from the intestinal lumen whereafter the compounds are passed into the bloodstream, either unchanged or as metabolites. In addition, lactic acid bacteria have been shown to increase colonic NADPH-cytochrome P-450 reductase activity (46) and glutathione S-transferase levels (9) and to reduce hepatic uridine diphosphoglucuronyl transferase activity (2), enzymes which are involved in the metabolism of carcinogens in rats.
Butyrate, a metabolite of some probiotic strains, promotes differentiation and apoptosis in a variety of colon tumour cell lines (10, 22). Apoptosis is a central feature in the regulation of cell number and the elimination of nonfunctional, harmful, or abnormal cells in the colon (21, 48). Therefore, apoptosis induced by butyrate could affect the removal of the DNA adducts from the colonic epithelium. Arimochi et al. investigated the effect of several strains of intestinal bacteria on the formation of azoxymethane (AOM)-induced aberrant crypt foci (ACF) and DNA adducts in the rat colon (3). They showed that culture supernatants of Lactobacillus acidophilus inhibited the ACF formation and that the inhibitory effect was due to the enhanced removal of O6-methylguanine from the colonic mucosa' DNA. They suggested that a metabolite of L. acidophilus in the culture supernatants might induce O6-methylguaninerepair enzyme, methylguanine-methyltransferase. Therefore, metabolites of probiotic bacteria might be inducing DNA-adduct-repair enzymes after exposure to mutagens found in the diet.
Lactic acid bacteria or a soluble compound produced by the bacteria may interact directly with tumour cells in culture and inhibit their growth (50, 54) . Lactic acid bacteria significantly reduced the growth and viability of the human colon cancer cell line HT-29 in culture and dipeptidyl peptidase IV and brush border enzymes were significantly increased, suggesting that these cells may have entered a differentiation process (6).
CONCLUDING REMARKS
Thus, a number of studies indicate that administration of bifidobacteria or lactobacilli alone or with fermentable carbohydrate (defined as a prebiotic) can alter colonic microflora populations and decrease the development of early preneoplastic lesions and tumours. However, several studies failed to demonstrate that bifidobacteria or lactobacilli administration alters colonic microflora or has effects on the host (8, 42). At present, the results from the epidemiological studies do not appear to support the results from experimental studies examining lactobacilli and colon cancer prevention. The reason for this is unclear but might be explained by differences in bacterial strains, with the strains being used in the experimental studies surviving better in the gastrointestinal tract than the strains present in fermented dairy products. It should also be emphasised that great care must be exercised in extrapolating the results of the above in vitro and animal studies to the human system. Many of the animal studies exploit specifically bred strains of mice and whether one can extrapolate antitumour activity in these animals to humans is somewhat unclear. It also must be kept in mind that the composition and metabolic activities of intestinal flora of experimental animals are significantly different from those of humans. Exploitation of human-flora-associated animals (germ-free animals inoculated with whole human intestinal flora) can be one of the solutions to this problem (20). Results of administering lactic cultures intravenously, intraperi-toneally and intralesionally (often used in animal studies) may not be compatible with oral consumption in humans. Many of the antitumour activities attributed to lactic cultures have been suggested to involve an enhanced function of the immune response. More work needs to be done to identify the specific strains and strain characteristics responsible for antitumour effects and the mechanisms by which these effects are mediated. However, even with these reservations in mind and mindful of the limited number of human studies described above, the use of lactic cultures for human cancer suppression is interesting, holds promise and certainly deserves more scrutiny. The latter should involve carefully designed clinical studies to corroborate the wealth of experimental studies.
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